Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.
Rheumatic fever (RF) and rheumatic heart disease (RHD) are postinfectious complications of an infection (or repeated infection) with the Gram-positive bacterium, Streptococcus pyogenes (also known as group A streptococcus, GAS). RF and RHD are global problems and affect many indigenous populations of developed countries and many developing countries. However, RF and RHD are only part of a larger spectrum of diseases caused by this organism. The development of a vaccine against GAS has primarily targeted the abundant cell-surface protein called the M-protein. This review focuses on different M-protein-based-subunit vaccine approaches and the different delivery technologies used to administer these vaccine candidates in preclinical studies.
Batzloff
Michael R
MR
The Cooperative Research Centre for Vaccine Technology and the Australian Centre for International Tropical Health and Nutrition, The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Brisbane 4029, Australia.
Pandey
Manisha
M
Olive
Colleen
C
Good
Michael F
MF
D000595:Amino Acid Sequence; D000818:Animals; D001425:Bacterial Outer Membrane Proteins / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D012213:Rheumatic Fever / Q000209:etiology / Q000517:prevention & control*; D012214:Rheumatic Heart Disease / Q000209:etiology / Q000517:prevention & control*; D022541:Streptococcal Vaccines / Q000276:immunology; D013297:Streptococcus pyogenes; D022223:Vaccines, Subunit
D001425:Bacterial Outer Membrane Proteins; D022541:Streptococcal Vaccines; D022223:Vaccines, Subunit